alpha-aminopyridine has been researched along with Dyskinesia Syndromes in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, B; Gu, X; He, Z; Li, W; Li, Y; Liu, Y; Wang, X; Williams, PR; Yu, B; Zhang, Q; Zhang, Y; Zhang, Z; Zhu, J | 1 |
| Iwashita, A; Matsuoka, N; Mihara, T | 1 |
| Davis, FA; Faut, M; Schauf, CL; Stefoski, D | 1 |
3 other study(ies) available for alpha-aminopyridine and Dyskinesia Syndromes
| Article | Year |
|---|---|
A Sensitized IGF1 Treatment Restores Corticospinal Axon-Dependent Functions.
Topics: Age Factors; Aminopyridines; Animals; Axotomy; Disease Models, Animal; Functional Laterality; Hindlimb; Insulin-Like Growth Factor I; Mice; Movement Disorders; Neurons; Osteopontin; Psychomotor Performance; Pyramidal Tracts; Recovery of Function; Reflex; Serotonin; Spinal Cord Injuries; Stroke; Time Factors | 2017 |
A novel adenosine A(1) and A(2A) receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: comparison with existing anti-Parkinson's disease drugs.
Topics: Aminopyridines; Analysis of Variance; Animals; Antiparkinson Agents; Callithrix; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Male; Motor Activity; Movement Disorders; MPTP Poisoning; Piperazines; Purinergic Antagonists; Time Factors | 2008 |
4-Aminopyridine improves clinical signs in multiple sclerosis.
Topics: 4-Aminopyridine; Adult; Aminopyridines; Flicker Fusion; Humans; Ion Channels; Male; Middle Aged; Movement Disorders; Multiple Sclerosis; Neural Conduction; Potassium; Sodium; Vision Disorders; Visual Acuity | 1987 |